Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		$ 100,330	$ 81,288	$ 41,651
Cost of sales	[1]	(34,344)	(30,821)	(8,484)
Selling, informational and administrative expenses	[1]	(13,677)	(12,703)	(11,597)
Research and development expenses	[1]	(11,428)	(10,360)	(8,709)
Acquired in-process research and development expenses	[2]	(953)	(3,469)	(684)
Other income/(deductions)—net		(217)	4,878	(1,213)
Collaborative Arrangement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues—Revenues	[3]	437	590	284
Revenues—Alliance revenues	[4]	8,537	7,652	5,418
Total revenue		8,974	8,241	5,703
Cost of sales	[5]	(15,589)	(16,169)	(61)
Selling, informational and administrative expenses	[6]	(196)	(175)	(194)
Research and development expenses	[7]	272	314	(14)
Acquired in-process research and development expenses	[8]	(339)	(1,056)	(179)
Other income/(deductions)—net	[9]	$ 664	$ 820	$ 567

[1] Exclusive of amortization of intangible assets.

[2] See Note 1L.

[3] Represents sales to our partners of products manufactured by us.

[4] Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2022 reflects increases in Alliance revenues from Eliquis, Comirnaty and Bavencio, while the increase in 2021 reflects increases in Alliance revenues from Comirnaty, Eliquis and Xtandi.

[5] Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The decrease in 2022, as well as the increase in 2021, primarily relate to Comirnaty.

[6] Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.

[7] Represents net reimbursements (to)/from our partners for research and development expenses incurred.

[8] Primarily relates to upfront payments to our partners as well as premiums paid on our equity investments in the common stock of our partners.

[9] Primarily relates to royalties from our collaboration partners.